Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.41 |
| ▸ | KIT | P10721 | 9/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28336000 | 0.86 | CSF1R (0.51) | CSF1RKITNPC1POLBRAB9A | |
| SCHEMBL6976989 | 0.86 | EGFR (0.45) | CSF1RKITEGFRERBB2NPC1 | |
| SCHEMBL13814708 | 0.83 | ALDH1A1 (0.47) | POLB | |
| SCHEMBL9975354 | 0.79 | PLK1 (0.43) | FFAR4ERBB2APPNPC1POLB | |
| SCHEMBL6979978 | 0.79 | FFAR4 (0.54) | FFAR4APPL3MBTL1 | |
| SCHEMBL6977010 | 0.77 | ERBB2 (0.57) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL22169906 | 0.76 | MAPT (0.51) | FFAR4FFAR1GAANPC1RAB9A | |
| SCHEMBL22169907 | 0.75 | MRGPRX4 (0.55) | FFAR4 | |
| SCHEMBL2250509 | 0.75 | EGFR (0.52) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL6980764 | 0.73 | MRGPRX4 (0.54) | EGFRERBB2GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | CSF1R 476/4885KIT 409/4885FFAR4 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.